Privat Doktor Egeszseguegyi Szolgaltato Zrt.
- Address
- lock Available on a paid plan
Cardiovascular Diseases
The cardiology department at Privat Doktor Egeszsegugyi Szolgaltato Zrt. conducts a broad portfolio of studies aimed at major cardiovascular diseases including atherosclerotic disease, atrial fibrillation, heart failure, and hypertension, with the goal of testing new therapies and improving patient outcomes.
- Reducing major adverse cardiovascular events in high‑risk populations
- Preventing stroke in patients with atrial fibrillation unsuitable for anticoagulation
- Slowing chronic kidney disease progression in individuals with hypertension
- Improving survival and hospitalization rates in heart failure with preserved or reduced ejection fraction
- Targeting elevated lipoprotein(a) and LDL‑C levels
- Assessing anti‑inflammatory interventions after myocardial infarction
Based in Budapest, the centre has launched 19 trials with five investigators, partnering with academic and industry collaborators to evaluate innovative drugs and combination regimens for cardiovascular risk reduction.
Nutritional and Metabolic Diseases
Research at the site also focuses on nutritional and metabolic disorders, addressing obesity, type 2 diabetes, hyperlipidemia, and severe hypertriglyceridemia, with studies designed to test novel agents that modify metabolic pathways and improve clinical outcomes.
- Evaluating therapies that lower fasting triglyceride concentrations
- Testing weight‑loss agents that also improve glycemic control
- Investigating treatments that reduce lipoprotein(a) and LDL‑C in inherited hypercholesterolemia
- Exploring combination regimens for hypertension in patients with metabolic syndrome
- Assessing drugs that prevent acute pancreatitis in severe hypertriglyceridemia
The Budapest facility leverages its multidisciplinary expertise to advance therapeutic options for metabolic disease, contributing to the growing evidence base that links metabolic health with cardiovascular risk.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 8 by active trials.
- 1AstraZeneca AB3active
lock +7 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB6trials
lock +3 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Privat Doktor Egeszseguegyi Szolgaltato Zrt.
lock Showing 1 of 19 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Plozasiran in Adults with Severe Hypertriglyceridemia | Arrowhead Pharmaceuticals Inc. | Phase III | Not Recruiting | Oct 2024 | — |
IMP list
lock Showing 1 of 11 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Synthetic Double-Stranded Sirna Oligonucleotide Directed Against Apolipoprotein C-Iii Mrna And Covalently Linked To A Ligand Containing Three N-Acetylgalactosamine Residues | 4 | Unknown | 2024-10-31 | 2025-12-08 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.